MABA: dual mechanism of action
“The newly developed compound AZD8871 works both as a LABA, and as a LAMA”, declared Dr Ioannis Psallidas (Medical Science Director, AstraZeneca, and University of Oxford, UK) . It is a long-acting, bi-functional bronchodilator agent, combining muscarinic antagonist and β2-adrenoceptor agonist activities in a single molecule (MABA, Figure 4) .
Figure 4: MABA: molecular structure concept with 3 elements 
Until now, four phase 1 studies have been performed to study this new MABA. Single and multiple doses of AZD8871 administered in healthy volunteers and patients with asthma or COPD showed that AZD8871 is safe and efficacious in terms of lung function. Especially in COPD patients, a single dose of AZD8871 (400 µg or 1800 μg) demonstrated a sustained bro...
please login to read the entire article:
You need to register to read the entire article, please do so now.
Table of Contents: ERS 2018
COPD: Triple therapy, MABA and antibiotics
Current look on asthma
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.